The Effect of Combined Iron Protocols on Perioperative Allogeneic Transfusion

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University

About this trial

The goal of this clinical trial is to learn if a combined iron supplementation regimen can reduce the need for blood transfusions in adults with iron-deficiency anemia undergoing major elective cardiac surgery. The trial will also look at whether this regimen is safe and well tolerated. The main questions it aims to answer are:

Does the combined regimen lower the amount of allogeneic red blood cell transfusion needed during and after surgery?

Are there any side effects or safety concerns associated with the regimen?

Researchers will compare the combined iron supplementation (sucrose iron, erythropoietin, and vitamin C) to standard care to see if it helps reduce blood transfusions.

Participants will:

Receive either the combined regimen or standard care before surgery

Undergo major elective cardiac surgery under general anesthesia

Be monitored for blood transfusion needs and recovery up to 90 days after surgery

Eligibility criteria

Qualifiers

Participants must be at least 18 years of age.

Major cardiac surgery should encompass procedures such as coronary artery bypass grafting (CABG), valve surgery, or a combination of both.

Iron deficiency anemia is defined as having a ferritin level below 100 μg/L or a ferritin level below 300 μg/L accompanied by a transferrin saturation below 25%. Additionally, hemoglobin levels should range between 90 and 130 g/L for men or between 90 and 120 g/L for women.

The American Society of Anesthesiologists (ASA) classification should fall within Grade 1-3.

Disqualifiers

Contraindications for the administration of iron sucrose, ascorbic acid, or rHuEPO.

Presence of a temperature exceeding 37.5 °C or the utilization of non-prophylactic antibiotics.

Individuals with a weight equal to or less than 50kg.

Individuals with a family history of haemochromatosis or thalassaemia, or those with a transferrin saturation level exceeding 50% or a documented history of iron overload.

Trial design

Treatments tested in this trial

  • Iron sucrose, Human Erythropoietin Injection, Vitamin C
  • Standard Medical Care

Treatment groups

400 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Second Affiliated Hospital, School of Medicine, Zhejiang University

Lead sponsor

First Affiliated Hospital of Wenzhou Medical University

Collaborator

Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University

Collaborator

The Central Hospital of Lishui City

Collaborator

First Affiliated Hospital of Chongqing Medical University

Collaborator

Zhejiang Provincial People's Hospital

Collaborator

The Fourth Affiliated Hospital of Zhejiang University School of Medicine

Collaborator

Zhejiang University

Collaborator

Affiliated Hospital of Nanjing University of Chinese Medicine

Collaborator